Lactobacillus acidophilus surface layer protein a (slpa) as a therapeutic agent for the treatment of inflammatory diseases
US-2021300973-A1 · Sep 30, 2021 · US
Surface layer protein a (SlpA) as a therapeutic agent for the treatment of inflammatory diseases
US12098170B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12098170-B2 |
| Application number | US-202218568888-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 10, 2022 |
| Priority date | Jun 11, 2021 |
| Publication date | Sep 24, 2024 |
| Grant date | Sep 24, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to synthesize surface layer protein A (SlpA). Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant bacterium, for example L. lactis cells, or a therapeutically effective amount of the isolated SlpA. The recombinant bacteria cells or SlpA isolated from the recombinant bacteria can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient.
First claim
Opening claim text (preview).
We claim: 1. An isolated bacterial surface layer protein A (SlpA) protein comprising SEQ ID NO: 5. 2. The SlpA protein of claim 1 , wherein the protein: a) comprises a molecular label conjugated to the protein, or b) is a multimeric protein. 3. The SlpA protein of claim 2 , wherein the molecular label is a radiolabel, fluorescent label, affinity label or targeting label. 4. A composition comprising the SlpA protein according to claim 1 and a pharmaceutically acceptable carrier and/or excipient, optionally in combination with sulfasalazine, cyclosporine, prednisone, methylprednisone, budesonide, mesalamine, azathioprine, tumor necrosis factor (TNF) inhibitors, methotrexate, 6-mercaptopurine, a corticosteroid, infliximab or combinations thereof. 5. A recombinant bacterium genetically modified to express a surface layer protein A (SlpA) comprising SEQ ID NO: 5. 6. The recombinant bacterium of claim 5 , wherein said recombinant bacterium secretes SlpA. 7. The recombinant bacterium of claim 5 , wherein said recombinant bacterium is selected from the group consisting of Lactococcus ( L .) chungangensis, L. formosensis, L. fujiensis, L. hircilactis, L. garvieae, L. lactis, L. laudensis, L. nasutitermitis, L. piscium, L. plantarum, L. raffinolactis , and L. taiwanensis. 8. The recombinant bacterium of claim 7 , wherein said recombinant bacterium is L. lactis. 9. The recombinant bacterium of claim 5 , wherein said recombinant bacterium is a lactic acid bacterium. 10. The recombinant bacterium of claim 9 , wherein said lactic acid bacterium is a Lactococcus species. 11. A probiotic food comprising the recombinant bacterium of claim 5 . 12. The probiotic food of claim 11 , wherein the food is yogurt, fermented vegetable, kefir, sauerkraut, miso soup, pickle, tempeh or kimchi.
Assignees
Inventors
Classifications
Bacteria or derivatives thereof, e.g. probiotics · CPC title
Lactobacillus acidophilus · CPC title
- C07K14/335Primary
from Lactobacillus (G) · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
from bacteria · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12098170B2 cover?
- The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to synthesize surface layer protein A (SlpA). Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombin…
- Who is the assignee on this patent?
- Univ Florida, Rise Therapeutics Llc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/335. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).